Literature DB >> 22210180

Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis.

Kenzo Takada1.   

Abstract

Epstein-Barr virus (EBV)-encoded small RNA (EBER) is the most abundant EBV viral transcript and is used as a target molecule to detect EBV-infected cells in tissues by in situ hybridization. EBER is expected to form double-stranded RNA-like structures. The results of the present study show that EBER contributes to oncogenesis by modulating innate immunity in patients with NPC and Burkett's lymphoma. BARF1 is a homolog of the human proto-oncogene c-fms and is expressed as a latent gene in NPC. Reconstitution of NPC-type EBV infection using NPC-derived cell lines shows that BARF1 contributes to the tumorigenicity of NPC cells. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210180     DOI: 10.1016/j.semcancer.2011.12.007

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  31 in total

1.  Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.

Authors:  E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin
Journal:  Pathol Oncol Res       Date:  2020-06-21       Impact factor: 3.201

2.  Multipronged attenuation of macrophage-colony stimulating factor signaling by Epstein-Barr virus BARF1.

Authors:  Ann Hye-Ryong Shim; Rhoda Ahn Chang; Xiaoyan Chen; Richard Longnecker; Xiaolin He
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

3.  Necrosis Factor-α (TNF-α) and the Presence of Macrophage M2 and T Regulatory Cells in Nasopharyngeal Carcinoma.

Authors:  Iffah Mardhiyah; Yustina Nuke Ardiyan; Siti Hamidatul Aliyah; Enda Cindylosa Sitepu; Camelia Herdini; Ery Kus Dwianingsih; Fatin Asfarina; Sumartiningsih Sumartiningsih; Jajah Fachiroh; Dewi Kartikawati Paramita
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

Review 4.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

Review 5.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

Review 6.  Epstein-Barr virus: more than 50 years old and still providing surprises.

Authors:  Lawrence S Young; Lee Fah Yap; Paul G Murray
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

Review 7.  Epstein-Barr virus infection and nasopharyngeal carcinoma.

Authors:  Sai Wah Tsao; Chi Man Tsang; Kwok Wai Lo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

8.  Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma.

Authors:  Z Zeng; S Fan; X Zhang; S Li; M Zhou; W Xiong; M Tan; W Zhang; G Li
Journal:  Clin Transl Oncol       Date:  2015-08-11       Impact factor: 3.405

Review 9.  Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy.

Authors:  Raymond Wai-Ming Lung; Joanna Hung-Man Tong; Ka-Fai To
Journal:  Int J Mol Sci       Date:  2013-08-23       Impact factor: 5.923

10.  Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic.

Authors:  Benjamin Vérillaud; Mélanie Gressette; Yannis Morel; Carine Paturel; Philippe Herman; Kwok Wai Lo; Sai Wah Tsao; Michel Wassef; Anne-Sophie Jimenez-Pailhes; Pierre Busson
Journal:  Infect Agent Cancer       Date:  2012-12-03       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.